Biogen: Biogen's Diranersen Shows Clinical Benefit, Robust Tau Reduction In Phase 2 Alzheimer's Study.
WESTON (dpa-AFX) - Biogen Inc. (BIIB) on Tuesday reported detailed results from the Phase 2 CELIA study of its experimental Alzheimer's disease treatment diranersen, showing the drug slowed clinic...
Read full article »
Biogen is a Massachusetts-based biotechnology company that researches and develops novel therapies for the treatment of neurological diseases across the globe.
Read more